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Aim: Gonadal hormones are essential for reproductive function, but can act on neural 
and other organ systems, and are probably the cause of the large majority of known sex 
differences in function and disease. The aim of this review is to provide evidence for this 
hypothesis in relation to eye disorders and to retinopathies in particular.
Methods: Epidemiological studies and research articles were reviewed.
Results: Analysis of the biological basis for a relationship between eye diseases and 
hormones showed that estrogen, androgen, and progesterone receptors are present 
throughout the eye and that these steroids are locally produced in ocular tissues. Sex 
hormones can have a neuroprotective action on the retina and modulate ocular blood 
flow. There are differences between the male and the female retina; moreover, sex 
hormones can influence the development (or not) of certain disorders. For example, 
exposure to endogenous estrogens, depending on age at menarche and menopause 
and number of pregnancies, and exposure to exogenous estrogens, as in hormone 
replacement therapy and use of oral contraceptives, appear to protect against age- 
related macular degeneration (both drusenoid and neurovascular types), whereas exog-
enous testosterone therapy is a risk factor for central serous chorioretinopathy. Macular 
hole is more common among women than men, particularly in postmenopausal women 
probably owing to the sudden drop in estrogen production in later middle age. Progestin 
therapy appears to ameliorate the course of retinitis pigmentosa. Diabetic retinopathy, a 
complication of diabetes, may be more common among men than women.
Conclusion: We observed a correlation between many retinopathies and sex, probably 
as a result of the protective effect some gonadal hormones may exert against the devel-
opment of certain disorders. This may have ramifications for the use of hormone therapy 
in the treatment of eye disease and of retinal disorders in particular.
Keywords: gonadal hormones, estrogens, hormone therapy, eye disorders, retinopathies, optic nerve, age-related 
macular degeneration, sex-related differences
iNTRODUCTiON
There is a growing body of evidence for the importance of gonadal hormone action in the func-
tion of the reproductive and other systems (1), including bone (2) and cardiovascular system. Sex 
hormones (androgenic, estrogenic, and progestinic) are produced by both sexes, though the quantity 
and mode differ by sex and age. Moreover, they are produced, not only by the gonads, but also by 
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other organs (3, 4), including the central nervous system (CNS) in 
which estrogens are thought to exert a neuroprotective role (5, 6).
Historically, interactions between gonadal hormones and the 
eye have received scarce attention; however, recent research into 
sex-related differences has begun to reveal possible links between 
estrogens and eye diseases, i.e., glaucoma, age-related macular 
degeneration (AMD), and cataracts. This has carried over into 
the evaluation of the implications that postmenopausal hormone 
replacement therapy (HRT) and anti-estrogenic therapy in breast 
cancer could have for concomitant eye disorders (7).
Since, research in this area is still at its beginning, the avail-
able studies are few and often limited in sample size; this does 
not allow to reach a univocal and definitive answer about the 
relationship between sex, sex hormones, and ocular pathologies. 
The purpose of this review is, therefore, to summarize the results 
currently present in the literature.
BASiCS OF BiOLOGY AND 
ePiDeMiOLOGY OF iNTeRACTiON 
BeTweeN GONADAL HORMONeS  
AND THe eYe
Presence of Hormone Receptors in the 
Human eye
The eye was long considered a “sexually neutral” structure, mean-
ing that it was believed that there were no differences in ocular 
physiology and pathology between the sexes. Today, however, we 
know that differences among sexes exist both in the physiology 
and in the pathology of the eye. In fact, the eye is a target for 
sex steroid hormones as demonstrated by the large presence of 
sex steroid hormone receptors (SSHRs). The SSHRs’ mRNAs are 
present everywhere in the eye (8): cornea, lens, iris, ciliary body, 
retina, lacrimal gland, meibomian gland, conjunctiva [for a com-
plete list of citations see Ref. (9)]. In all these locations, estrogen 
receptor α (ERα), estrogen receptor β (ERβ), progesterone recep-
tor, and androgen receptor (AR) mRNAs have been detected.
The distribution of SSHRs in the eye varies by sex and age, which 
partly explains the difference in the epidemiology of certain eye 
diseases (9). PCR assay, Western blot, and immunohistochemical 
analysis have demonstrated the presence of ER-α protein in the 
retina and RPE of young women, but not in postmenopausal 
women or men (10).
In addition to AR mRNA (8), the AR protein is present in 
the lachrymal and meibomian glands, the cornea, the bulbar 
conjunctiva, the lens, and the RPE, together with 5α-reductase 
(the enzyme converting testosterone into the more powerful 
dihydrotestosterone, DHT) type 1 and 2 mRNA (8).
Synthesis of Steroids in the Retina
The mammalian retina has the ability of synthetize neurosteroids 
(pregnenolone, progesterone, dehydroepiandrosterone, desoxy-
corticosterone, 3 alpha, 5 alpha-tetrahydrodesoxycorticosterone, 
3 alpha-hydroxy-5 alpha-dihydro-progesterone, 17-hydroxypro-
gesterone, and 17-hydroxypregnenolone) from cholesterol, as 
demonstrated by using retinal explants, thus excluding interfer-
ences from circulating steroids (11).
Following studies demonstrated also the presence of steroido-
genic enzymes (mRNA and protein) in the retina (12): cytochrome 
CYP11A1 (CYP450scc) that converts cholesterol in pregnenolone; 
3-β-hydroxysteroid dehydrogenase which converts pregnenolone 
in progesterone; cytochrome CYP17A1 (P450c17) involved in the 
production of 17-α-hydroxymetabolites; and CYP19A1 (P450 
aromatase) which converts testosterone in 17-β-estradiol [(11, 13, 
14), Figure 1]. Cholesterol, which activates the metabolic cascade 
leading to the production of E2, is also produced in the retina: 
HMG-CoA reductase, the main enzyme for cholesterol synthesis, 
is present in the RPE, photoreceptors, and Müller cells. Exogenous 
cholesterol, on the other hand, is derived from high-density and 
low-density lipoproteins (HDL and LDL, respectively) that bind 
to specific receptors of the retinal cells (15). The principal limiting 
steps for estrogen production in the retina are the regulation of 
CYP450scc and aromatase enzymatic activities (14) (Figure 1). 
The steroidogenic enzymes are found in retinal neurons, glial 
cells, and photoreceptors in amounts similar to those observed 
in other part of the CNS (16). Enzymes’ concentration is greatest 
in the internal nuclear layer, which is considered the principal site 
of retinal steroids’ synthesis (14).
Finally, it is important to note that estrogens and androgens are 
also produced outside the retina (gonads, adrenals) and, through 
the blood flow, they can reach the eye where, in males, circulat-
ing testosterone may be locally metabolized in 17-β-estradiol. 
Diseases or functional alterations linked to steroid hormones 
may, therefore, be due to both retinal steroidogenic enzyme fail-
ure (short-term effects?), alterations in the gonadal and adrenal 
hormone supply (long-term effects?), or both conditions.
Differences in Retinal Function  
between Men and women
There are marked sex-related differences in ocular anatomy and 
pathophysiology, particularly for the retina. Studies on mice 
have identified differences in retinal structure between males 
and females and found that, as measured by multifocal electro-
retinography (mfERG), retinal function is better in females of 
reproductive age than in males and older females (17). Similar 
mfERG studies on humans found a statistically significant differ-
ence in neuroretinal function between men and women below 
50 years, but not after this age; in addition, neuroretinal function 
was lowest in women who received a hysterectomy during repro-
ductive age, with subsequent iatrogenic-induced menopause. 
These findings suggest that the estrogenic cycle has a beneficial 
effect on neuroretinal function and that estrogens may have a 
protective role (18).
Sex-Related Differences in the  
Prevalence of eye Disorders
Sex-related differences in eye anatomy and physiology are 
reflected in disease processes (19). Cataracts, for example, are far 
more prevalent among women than men: the prevalence of lens 
opacities in women aged between 65 and 74 years is 24–27%, but 
only 14–20% in their male counterparts (20–23). Estrogen levels, 
besides other risk factors, appear to play a role. Numerous studies 
have shown that HRT is a protective factor in postmenopausal 
FiGURe 1 | Neurosteroid synthesis in the retina. The drawing report of the metabolic pathway leading to estradiol synthesis within the retina (11, 14). The 
steroidogenic enzymes already identified for their mRNA, activity or immunolocalization are indicated within yellow boxes. The enzymes still lacking of identification 
are indicated within the grey boxes. Dotted lines indicate so far unclear enzymatic activities. Abbreviations: 3β-HSD, 3β-hydroxysteroid dehydrogenase; 3α-HSD, 
3α-hydroxysteroid dehydrogenase; 5αDH-DOC, 5 alpha-dihydrodeoxycorticosterone; 5αDHP, 5α-dihydroprogesterone; 5α-R, 5α-Reductase; 17β-HSD1, 
17β-hydroxysteroid dehydrogenases 1; 17β-HSD4, 17β-hydroxysteroid dehydrogenases 4; 17β-HSD5, 17β-hydroxysteroid dehydrogenases 5; DHEA, 
dehydroepiandrosterone; DHT, dihydrotestosterone; DOC, deoxycorticosterone; HMG-CoA, hydroxymethylglutaryl-CoA; HMGCoA-R, hydroxymethylglutaryl-CoA 
reductase.
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women and that late menopause or early menarche, both of 
which augment estrogen exposure, lower the risk of cataracts in 
advanced age (24–27). The main protective action of estrogens on 
the lens is probably due to their antioxidant properties (28). With 
the onset of menopause, the drop in estrogen levels increases the 
risk of cataracts in older women. Differently, the levels of estrogen 
converted by aromatase from testosterone in men do not seem 
to be age dependent, affording men greater protection against 
the development of cataracts (29). This sex-related difference in 
eye disorders is not always so distinct. For example, sex is not 
considered a factor in AMD (30, 31), though some studies have 
suggested its higher prevalence among women (32, 33). When 
distinguished by type of AMD, neovascular (34) and drusenoid 
(32) forms are more prevalent among women. As reported for 
cataracts, longer exposure to estrogens or HRT confers a lower 
risk of developing AMD in later age (35, 36), suggesting that 
this is due to the antioxidant and anti-inflammatory actions of 
estrogen (37, 38).
Glaucoma is also more frequent in women (39), though this 
is more likely linked to the longer life expectancy of women 
and as such is an age-related risk factor (40). Nonetheless, 
sex-related differences have been associated with different types 
of glaucoma: a study conducted on an Asian population (39) 
reported that angle-closure glaucoma is more prevalent among 
women; other studies reported the same findings for white and 
black populations (41, 42), but other studies found that, after 
adjusting for age and population, angle-closure glaucoma is 
more common among men (40, 43). Sex-related differences in 
the prevalence of diabetic retinopathy are associated with the 
difference in the prevalence of diabetes. Though more men than 
women are affected by type 1 diabetes (44) no study to date has 
found a significant difference in its prevalence (45, 46). Similarly, 
no statistically significant sex-related differences in the preva-
lence of diabetic retinopathy associated with type 2 diabetes 
have been established, though some studies have suggested that 
it is more frequent among men (47, 48).
Various other risk factors besides sex alone need to be taken 
into account (49). For example, in a study on a rural south Indian 
population, Nirmalan et  al. (50) tried to understand if female 
reproductive factors (age at menarche and menopause, number of 
pregnancies, etc.) were related with eye diseases. The study found 
no association with cataracts, open-angle glaucoma, macular 
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degeneration, or myopia; nonetheless, the study presented several 
limitations, including the fact that the data on reproductive fac-
tors were gleaned from self-report questionnaires and that eye 
disorders were diagnosed in most subjects during the course of 
the study.
NeUROPROTeCTive eFFeCT OF SeX 
HORMONeS
Preclinical Studies
Several studies have investigated whether estrogens have a neuro-
protective role and, if so, through which mechanisms they exert 
such action. Nixon et  al. (51) examined the role of hormones 
in elevated levels of glutamate, which has a neurotoxic effect. 
High glutamate concentrations inhibit the cysteine/glutamate 
transporter, which reduces the production of glutathione, an 
antioxidant. This decrease leads to the augmented production of 
reactive oxygen species (52), which, owing to oxidative damage, 
promote the development of eye diseases, such as AMD (53) 
and retinitis pigmentosa (54). The experiment was carried out 
in  vitro on 661  W cells, i.e., a mouse cone photoreceptor cell 
line, and demonstrated that E2 and the non-feminizing estrogen 
analogs ZYC-26 and ZYC-3 exert a protective action against the 
damage induced by 5 µM of glutamate. It was also observed that 
the protective effect of ZYC-26 and ZYC-3 is not exerted via the 
classic estrogen receptors ERα and ERβ, as demonstrated by the 
persistent protective action despite the use of an estrogen recep-
tor pan-antagonist (ICI182780) and the lack of a protective effect 
after the use of the two agonists of ERα and ERβ. Based on these 
results, it was hypothesized that non-feminizing hormones could 
be used in the treatment of neurodegenerative eye disorders, 
and thus avert the side effects of prolonged estrogen therapy. Mo 
et al. (55) investigated intracellular neuroprotective mechanisms 
in ovariectomized mice, as measured by electroretinography of 
light-induced apoptosis in retinal cells. Following intravitreal 
administration of 17β-estradiol, retinal function was preserved 
due to the reduction of neuronal apoptosis. The involved path-
way is PI3k/Akt activation: administration of a PI3K inhibitor 
(LY294002) increases retinal neuronal apoptosis, while the 
administration of estrogens leads to the translocation of NF-kB 
p65 from the cytosol to the nucleus, which is inhibited in the pres-
ence of LY294002. These results demonstrated that the protective 
action of estrogen on the retina is exerted via activation of the 
PI3K/Akt cascade and concludes with the nuclear translocation 
of NF-kB (55). The mechanism of action reported in this study 
is not the only one through which sex hormones exert their 
neuroprotective effect.
Estrogens also have a protective effect on intraretinal syn-
apses. Kaja et al. (56) used a mouse model in which mild retinal 
ischemia was induced by transient occlusion of the middle cer-
ebral artery. This experimental condition is ideal for examining 
the earliest stages of retinal damage that precede the development 
of neurodegenerative processes. Synaptic activity was measured 
using an immunoreactive technique based on the detection of 
Vesl-1L7Homer 1c (V-1L), a neuronal cytosolic protein involved 
in receptor clustering for neurotransmitters and in neuronal 
development and plasticity. V-1L is also a good marker to evalu-
ate the changes in synaptic connectivity during the early stages of 
apoptosis of retinal ganglion cells. The study (56) found that reti-
nal ischemia, though mild, can significantly reduce the number 
of V-1L-positive synapses in the internal plexiform layer of the 
retina, and increase the number of neuronal apoptotic cells in the 
ganglion cell layer. Estrogen administration exerts a protective 
effect by reducing the percentage of cells undergoing apoptosis 
and by preventing early ischemia-induced changes preceding 
apoptosis in the synaptic connections.
The neuroprotective action of estrogens appears to be closely 
linked to their antioxidant activity. Among the studies investigat-
ing this property, the early study by Moosmann et al. (57) merits 
mention as it demonstrated that the antioxidant-neuroprotective 
action of the hormones is not due to their genomic property, 
i.e., their ability to influence the transcription of specific genes, 
but rather because of their chemical properties as hydrophobic 
phenolic molecules. Estrogens were compared with other phenol 
molecules: the results showed that the protective effect against 
glutamate-induced oxidative toxicity in neuronal mouse cells 
was present in all the compounds studied and that the dose to 
obtain this effect was also the same. The study also showed that 
there is no correlation between estrogen strength and its anti-
oxidant properties. The discovery of the dissociation between 
the hormonal effect and the neuroprotective effect could open 
the way to the development of new therapies using molecules 
that possess the same protective properties as estrogens, but 
without the unwanted effects associated with their activities as 
sex hormones.
Nakazawa et al. (58) investigated differences in neuroprotec-
tive activity between “endogenous” estrogens (produced in ovary) 
and “exogenous” estrogens (administrated through intravitreal 
injection) in a mouse model by comparing their neuroprotec-
tive effects against retinal ganglion cell (RGC) death following 
axotomy of the optic nerve, which mimics glaucoma-induced 
RGC death. To evaluate endogenous estrogen activity, samples 
of retinal tissue from female mice, ovariectomized or not, served 
as controls in which RGC density was measured. While ovariec-
tomy had no effect on RGC density, the density was significantly 
reduced in mice that received ovariectomy and axotomy as 
compared to those that received only axotomy. These findings 
underscored the neuroprotective role of endogenous estrogens. 
In the evaluation of exogenous estrogens, ovariectomized mice 
administered intravitreal 17β-estradiol had a reduction in RGC 
death correlated with axotomy. The neuroprotective role of 
estrogens in this experimental condition indicates the potential 
for estrogen therapy in persons with etiologically similar eye 
diseases, such as glaucoma. In the second part of the study, the 
researchers wanted to identify the mechanism by which the exog-
enous estrogens exert their neuroprotective action. Immunoblot 
assay and immunohistochemical analysis showed that following 
intravitreal administration of E2, activation of the ERK signal 
transduction pathway, and c-Fos was augmented, whereas no 
change in PI3K/Act activation was observed. This finding was 
then confirmed in an experiment using U1026, an ERK inhibitor. 
Administration of U0126 before administration of E2 inhibited 
the neuroprotective effect of the estrogens (58).
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Another molecular mechanism by which estrogens exert their 
neuroprotective effect involves upregulation of stromal cell-
derived factor 1 (SDF-1). SDF-1 protects against retinal ischemia 
via its powerful chemotactic effect that promote tissue repair and 
the migration of stem cells produced in bone marrow to the site 
of damage (59). To demonstrate this factor’s mechanism of action, 
transient retinal ischemia was induced by increasing intraocular 
pressure (IOP) to 110  mm  Hg in a mouse model. Following 
reperfusion, the expected increase in mRNA and SDF-1 was 
measured via real-time PCR and Western blot. To evaluate the 
role of estrogens, E2 was administered peripherally before induc-
ing ischemia and SDF-1 was measured. The increased quantity 
of SDF-1 indicated that also in this condition estrogens play a 
neuroprotective role in reducing retinal damage (60).
Several studies aimed to determine whether only estrogens 
exerted neuroprotective action or other sex hormones, such as 
progesterone possessed similar properties (61). Progesterone was 
administered by peripheral infusion to one half of a population 
of male rats that had undergone photostress-induced retinal 
degeneration. Electroretinography showed no statistically sig-
nificant differences between the two cohorts. The study findings 
suggested that progesterone has no protective effects similar to 
those of estrogens.
Clinical Studies
In addition to preclinical animal studies, also clinical studies 
have been performed, including a population-based study in 
postmenopausal Korean women (62) in which the women were 
administered a questionnaire investigating their gynecological 
characteristics and whether they were taking estrogens as HRT. 
The women also received an eye examination, which revealed a 
higher prevalence of eye diseases, including anterior polar cata-
racts and other retinal disorders in the women not receiving HRT, 
suggesting its neuroprotective action.
eFFeCT OF SeX HORMONeS ON  
OCULAR BLOOD FLOw
Besides acting directly on retinal neuronal cells, sex hormones 
can also influence tissue perfusion by modulating retinal and 
choroid blood flow. A recent review of the literature (63) on sex 
differences in ocular blood flow sought to determine the possible 
role of sex hormones. The rationale for the study was derived 
from the fact that the eye diseases in which reduced blood flow 
is considered a causal or contributing factor, including AMD 
(64–66), glaucoma (67, 68), and diabetic retinopathy (69–71) 
are also those for which a sex-related correlation with prevalence 
has been found, suggesting that sex hormones may be implicated 
in the development of these diseases. Estrogens appear to play 
a protective role probably because of their vasodilatory action 
in reducing vascular resistance. This finding is shared by several 
studies that compared blood flow velocity and resistance of the 
ophthalmic artery and the central retinal artery in pre- and 
postmenopausal women. Blood flow velocity was higher and 
vascular resistance indices were lower in the premenopausal 
women (72), whereas vascular resistance of the central retinal 
artery was reduced after estrogen administration as compared to 
placebo (73). Retinal blood flow was higher in women receiving 
HRT than in those naïve to HRT (74); however, the evidence was 
not sufficiently strong to recommend HRT in the treatment of 
these conditions.
While estrogens exert a vasodilatory effect on retinal perfu-
sion, testosterone, like progesterone, has the opposite effect (72). 
Progesterone exerts a vasoconstrictive effect on ocular blood flow. 
As demonstrated by color Doppler imaging (75), progesterone 
increases the resistance of ophthalmic and retinal arteries. In 
women of reproductive age, progesterone was found to antago-
nize the vasodilatory effect of estrogen during the menstrual 
cycle, as measured with the pulsatility index of the central retinal 
artery (76).
The role of HRT has been extensively studied because of the 
implications it can have for postmenopausal women with eye 
diseases. Postmenopausal women receiving HRT or not were 
compared with regards to blood flow in the inferotemporal reti-
nal artery (ITRA), the peripapillary retina, and the margin of the 
optic nerve head, as measured using stereometric parameters and 
electroretinography (73). Blood flow in the ITRA was significantly 
higher and trophism of the optic nerve head and surrounding 
area was better in those receiving HRT. The effect of estradiol 
on retinal perfusion was investigated using ovariectomized mice; 
in this model E2 treatment improved retinal perfusion mainly 
through the increase in blood flow. Both HRT and administration 
of E2 exert a protective effect on the retina and the retinal nerve 
fiber layer by modulating tissue perfusion.
Harris-Yitzhak et al. (77) compared blood flow velocity in the 
retrobulbar arteries of postmenopausal women receiving HRT or 
not and young women of reproductive age. Hemodynamic resist-
ance in the ophthalmic artery was lower in the young women 
and those receiving HRT than in the postmenopausal women 
not receiving HRT, whereas central retinal artery blood flow was 
similar for all three groups. Blood flow in the posterior ciliary 
arteries was better in the young women than in the two groups 
of postmenopausal women in which blood flow was similar. 
These findings suggested that HRT may modulate resistance in 
the ophthalmic artery, whereas its effect on other arteries is less 
pronounced, since changes in blood perfusion in these areas seem 
to be related to age.
Other studies have compared the effect of estradiol and 
testosterone on ocular hemodynamics by measuring the serum 
levels of the two hormones in pre- and postmenopausal women 
not receiving HRT, in addition to evaluating via color Doppler 
blood flow velocity and vascular resistance in the ophthalmic 
and central retinal arteries (72). The findings showed that peak 
systolic blood flow velocity in the ophthalmic artery correlated 
with serum estradiol levels, whereas vascular resistance of the 
central retinal artery decreased with increasing levels of estro-
gens in both groups of women. Peak systolic blood flow velocity 
correlated negatively with serum testosterone levels in the pre-
menopausal women, whereas vascular resistance increased with 
higher testosterone levels. The two hormones were found to exert 
opposite effects: testosterone seemed to exert an antagonist effect 
as compared to estrogen.
The action of testosterone on ocular hemodynamics has also 
been studied in men, in which testosterone levels are naturally 
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higher than in women. Low testosterone levels correlated with 
hypertension and higher cardiovascular risk (78, 79). There 
are also population-based differences. In fact, Malan et al. (80) 
described differences for the cardiometabolic prognosis and 
intraocular perfusion pressure in two cohorts of black and 
white men aged between 28 and 68 years. Only in white men 
there was a positive correlation between free testosterone levels 
and retinal vessel diameter (except for the central retinal artery 
in which the vessel diameter was inversely proportional to 
testosterone levels). The findings suggested a population-based 
protective effect of testosterone on vascularization and retinal 
perfusion, probably linked to the vasodilatory effect in the 
microvasculature.
DiSeASeS OF THe ReTiNA, OPTiC 
NeRve, AND POSSiBLe SeX-ReLATeD 
eFFeCTS
In this section of the review we tried, for each pathology, to collect 
the evidence in favor of the correlation with sex hormones and 
those against (Table 1).
Age-Related Macular Degeneration
Evidence for the Protective Effect of Estrogens
Age-related macular degeneration is a progressive multifactorial 
eye disease that leads to deterioration of vision, loss of spatial and 
color vision, and adaptation to darkness (81–85). According to 
the World Health Organization, AMD is the cause of blindness 
in 10% of cases. Histological hallmarks are degeneration of the 
RPE, Bruch’s membrane, and the choriocapillaris, resulting in 
photoreceptor damage and death (86).
The pathogenesis of AMD is multifactorial: lipofuscin 
accumulation in the lysosomes of the RPE; extracellular drusen 
deposits between the RPE and the internal collagen layer of 
Bruch’s membrane; oxidative damage; and chronic inflam-
mation. Owing to their antioxidant and anti-inflammatory 
properties, estrogens might play a protective role in AMD 
(38). Beside these pathogenic factors there are genetic and 
environmental risk factors: age is perhaps the most important, 
in addition to smoking, obesity, atherosclerosis, hyperten-
sions, hypercholesterolemia, unhealthy diet, and history of 
cataract surgery (81). Female sex is a weak risk factor (32, 87, 
88) though exudative AMD is more common among women 
(34). These risk factors have been investigated in various stud-
ies. A case-control study (33) involved the participants in the 
Age-Related Eye Disease Study (AREDS) and used as controls 
subjects with fewer than 15 small drusen. Preliminary analysis 
showed that age was the main risk factor; subsequent analyses 
were accordingly adjusted for age to minimize its confounding 
with other factors. Smoking and hypertension both resulted as 
risk factors. Other correlated characteristics were Caucasian 
race, body-mass index, low educational level, hypermetropia, 
lens opacities, and female sex. A population-based study (89) 
identified alcohol abuse as another risk factor. Exposure to 
exogenous estrogens was a weakly protective factor against 
drusenoid deposit in AMD.
Spurred by the prospects of a protective action by estrogens 
against the development of AMD, researchers investigated the 
effect of HRT in postmenopausal women. Haan et al. (90) sought 
to determine whether HRT had a beneficial effect and whether 
different HRTs achieved different effects. They compared the 
efficacy of therapy based on conjugated equine estrogens (CEE) 
with CEE therapy combined with a progestinic. No associa-
tion was found between the use of either therapy and the early 
development of AMD, suggesting that the early stages of AMD 
are not influenced by HRT. In contrast, conjugate therapy was 
more effective than CEE therapy alone in reducing the risk of 
developing both the drusenoid and neovascular forms of AMD.
In addition to investigating the protective effect of HRT on 
the development of certain types of AMD, Feskanich et al. (91) 
examined the potential role of estrogens as oral contraceptives 
during reproductive age. They observed a lower risk for the 
development of neovascular AMD in women receiving HRT. 
The risk was further reduced in those who, in addition to HRT, 
had also taken oral contraceptives. An unexpected result was the 
correlation between the risk of early AMD and HRT. The risk of 
early AMD was higher in the women who had received HRT; 
this contrasted with other studies that reported no correlation 
between the two factors. When the gynecological characteristics 
(age at menarche and menopause, number of pregnancies) were 
analyzed, none of these reproductive factors significantly modi-
fied the risk of developing AMD, except for a slight reduction 
associated with multiple pregnancies.
Velez Edwards et al. (92) investigated whether genetic factors 
could interact with HRT in modulating the risk of AMD and 
found that postmenopausal HRT and use of estrogen oral con-
traceptives during reproductive age had a protective effect against 
AMD. When, however, the study population was stratified by 
AMD severity, i.e., distinguishing between early AMD character-
ized by geographic atrophy and neovascular AMD, the lower risk 
remained only for neovascular AMD. During the second part of 
the study, genetic analyses were carried out on peripheral blood 
samples to determine whether single nucleotide polymorphisms 
(SNPs) in genes thought to increase the risk of AMD could 
modulate the risk of AMD in association with HRT or previous 
exposure to oral contraceptives. The study findings showed that 
two SNPs of the ARMS2 gene (AMD 2) located on chromosome 
10 enhanced the positive effect of HRT in preventing AMD.
The hypothesis for a link between HRT and lower AMD 
incidence was investigated by other studies which showed that 
estrogen exerted a protective effect only against certain types 
of AMD, like drusenoid AMD, demonstrating that this type of 
AMD is more prevalent among women with multiple pregnan-
cies, whereas the correlation was not statistically significant when 
comparing early AMD and late AMD (93).
Other studies focusing attention on the role reproductive fac-
tors can have in the incidence of maculopathies. Blasiak et al. (37) 
reported a statistically significant reduction in the incidence of 
advanced AMD in women who had received HRT and a signifi-
cantly higher risk of developing advanced AMD in women who 
began menarche late. These findings demonstrated that estrogen 
exposure, including exogenous estrogens, plays a beneficial role 
in reducing the risk of advanced AMD. The hypothesis that early 
TABLe 1 | Role of sex hormones in ocular diseases.
++ + +/− / −
Protective 
effect
Modest 
correlation
Non-significant 
correlation
Non-associated 
factor
inversely correlated factor
Disease e P T Studies
AMD +/− / / Menopausal and reproductive factors and risk of age-related macular degeneration. Feskanich et al.
The effect of the hormone therapy on the risk for age-related maculopathy in postmenopausal women. Abramov et al.
Reproductive exposures, incident age-related cataracts, and age-related maculopathy in women: the Beaver Dam Eye Study. Klein et al.
Female reproductive factors and eye disease in a rural south Indian population: the Aravind comprehensive eye survey. Nirmalan et al.
/ Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. Chakravarthy et al.
Age-related macular degeneration guidelines for management. The Royal College of Ophthalmologists.
Sex steroid and AMD in older French women: the POLA study. Defay et al.
AMD
(drusenoid or 
neovascular)
++ Hormone therapy and age-related macular degeneration. The women’s health initiative sight exam study. Haan et al.
Inverse association of female hormone replacement therapy (HRT) with AMD and interaction with ARMS2 polymorphisms. Velez et al.
HRT, reproductive factors, and age-related macular degeneration: the Salisbury Eye Evaluation Project. Freeman et al.
Association between reproductive and hormonal factors and age-related maculopathy in postmenopausal women. Snow et al.
+ Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. Chakravarthy et al.
Risk factors for age-related macular degeneration. Evans
Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. Mitchell et al.
Risk factors associated with age-related macular degeneration: a case-control study in the age-related eye disease study (AREDS): AREDS report 
number 3. Group, AREDS research
Smoking, alcohol intake, estrogen use, and AMD in Latinos: the Los Angeles Latino Eye Study. Fraser-Bell et al.
CSCR / / − The potential role of testosterone in central serous chorioretinopathy. Grieshaber et al.
Central serous chorioretinis associated with testosterone therapy. Ahad et al.
Central serous chorioretinopathy in patients receiving exogenous testosterone therapy. Nudleman et al.
Finasteride for chronic central serous chorioretinopathy. Forooghian et al.
/ / / Serum cortisol and testosterone levels in chronic central serous chorioretinopathy. Tufan et al.
Serous central chorioretinopathy and endogenous hypercortisolemia. Kapetanios et al.
MACULAR 
HOLE
++ / / Clinical features of idiopathic macular cysts and holes. McDonnell et al.
Macular holes. James and Feman
Estrogen antagonist and development of macular hole. Chung et al.
Estrogen and macular holes: a postal questionnaire. Gray et al.
Systemic risk factors for idiopathic macular holes: a case-control study. Evans et al.
− / / Vitreous estrogen levels in patients with an idiopathic macular hole. Inokuchi et al.
Retinitis 
Pigmentosa
/ ++ / Enhancing survival of photoreceptor cells in vivo using the sintetic progestin norgestrel. Doonan et al.
Norgestrel may be a potential therapy for retinal degenerations. Doonan and Cotter
Neuroprotective actions of progesterone in an in vivo model of retinitis pigmentosa. Sanchez-Vallejo et al.
Diabetic 
Retinopathy
/ / +/− The role of sex hormones in diabetic retinopathy. Grisby et al.
Dehydroepiandrosterone protects bovine retinal capillary pericytes against glucose toxicity. Briganrdello et al.
++
If early stage
−
If late stage
/ Gender and estrogen supplementation increases severity of experimental choroidal neovascularization. Espinosa-Heidmann et al.
Effects of tamoxifen versus raloxifene on retinal capillary endothelial cell proliferation. Grigsby et al.
/ / / Exogenous estrogen exposures and changes in diabetic retinopathy: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Klein et al.
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menopause (before age 45 years), because it reduces the duration 
of exposure to estrogens, could constitute a risk for the develop-
ment of macular degeneration was evaluated by Vigerling et al. 
(94) who compared different samples of women, including those 
that had experienced spontaneous early menopause and others 
who had experienced iatrogenic early menopause following 
ovariectomy. The results showed no increased risk for AMD 
among the women who experienced spontaneous early meno-
pause, whereas the risk of developing macular degeneration was 
significantly increased in those who had undergone ovariectomy 
before age 45 years.
Studies Showing No Protective Effect of Estrogens
While some studies have found a neuroprotective effect of 
estrogens, others have not, leaving the question of their potential 
neuroprotective effect open. The guidelines for the management 
of AMD issued by the Royal College of Ophthalmologists (95) 
state that, on the basis of a meta-analysis (32), female sex is not 
a factor associated with higher risk of AMD. The guidelines go 
on to state that the higher prevalence of AMD among women is 
largely due to their longer life expectancy (87).
Numerous studies cited by the guidelines report that repro-
ductive characteristics, e.g., age at menarche and menopause, 
and exposure to HRT are inconsistently associated with 
AMD (50, 96–98). The POLA study, for example, found that 
advanced AMD and drusenoid AMD or AMD with pigment 
abnormalities were not associated with oophorectomy or hys-
terectomy or HRT exposure. The POLA study examined serum 
levels of diverse hormones and correlated molecules (estradiol, 
testosterone, DHEAS, sex hormone-binding globulin) and 
found a correlation, albeit weak, only for high DHEAS levels 
that appeared to be associated with an increased prevalence of 
drusenoid AMD. Other studies and a review corroborate the 
hypothesis for the lack of a correlation between estrogens and 
macular degeneration. A systematic review (32) of 18 popula-
tion-based studies and 6 case-control studies on the strength 
of the relationship among factors, increasing the risk for AMD 
reported that the risk factors most strongly correlated with 
degenerative maculopathy were age, smoking (33, 99, 100), his-
tory of cataract surgery (101–103), and family history of AMD 
(104, 105). Moderately correlated factors were body-mass index 
(99), history of cardiovascular disease (99, 106), hypertension 
(99, 106, 107), and elevated plasma fibrinogen (108). Factors 
weakly or inconsistently correlated with AMD were sex (107, 
109, 110), ethnic group (107, 111), color of iris (104), history of 
cardiovascular disease (99, 106) and serum levels of cholesterol 
(99, 106), and triglycerides (106). Female sex was not consid-
ered a risk factor, precluding the role of sex hormones in higher 
risk for the disease.
Central Serous Chorioretinopathy (CSCR)
Evidence of the Association between CSCR and Sex 
Hormones: Testosterone and Increased Risk of 
CSCR
Central serous chorioretinopathy is an acquired eye disease 
characterized by exudative detachment of the retinal and/or the TA
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RPE. Its pathogenesis is not yet fully understood; however, it is 
thought that alterations in choroid circulation and RPE function 
may be implicated in the development of the disease. This notion 
is corroborated by findings from fluorangiography and OCT 
that document augmented capillary permeability and pressure 
of the choroid vessels (107, 108). Risk factors vary widely from 
psychosocial stress to type A personality, Cushing’s syndrome, 
infections, smoking, alcohol, to pregnancy, and steroid therapy 
(109–111), all of which are characterized by elevated serum levels 
of glucocorticoids (112–114).
Given its higher prevalence among men, androgens have been 
directly implicated in the pathogenesis of CSCR (111, 115). In 
their study, Nudleman et  al. (116) examined patients receiving 
exogenous testosterone therapy and who had no known risk 
factors for CSCR. The results showed that testosterone therapy is 
a probable independent risk factor for CSCR; moreover, disease 
symptoms and subretinal fluid accumulation resolved after 
discontinuation of testosterone therapy. Further evidence for the 
role of testosterone came from a case report of a woman who 
was not pregnant while receiving testosterone therapy (111), and 
another case report of a male population receiving testosterone 
therapy for hypogonadotropic hypogonadism (115), the latter of 
which demonstrated a temporal correlation between administra-
tion of therapy and the development of CSCR, indicating both 
testosterone and estrogen as the cause. Given the link between 
testosterone and CSCR, finasteride, an inhibitor of DHT synthe-
sis, was considered as an alternative in the treatment of CSCR. 
Forooghian et  al. (117) investigated the effect of finasteride 
administered for 6  months and monitored changes in visual 
acuity, macular thickness, subretinal fluid accumulation, OCT, 
serum DHT and testosterone, and cortisol levels in urine. Though 
no changes in visual acuity occurred, macular thickness and 
subretinal fluid level were lowest at 3 months in therapy before 
increasing slightly though remaining below basal reference 
limits. Furthermore, macular thickness and subretinal fluid both 
increased after therapy was discontinued in four patients and 
normalized in the patients who continued with therapy. These 
findings suggest a possible role for finasteride in the treatment of 
chronic CSCR.
Studies Showing an Absence of Association between 
CSCR and Testosterone
The study of Kapetanios et al. (114) reported a statistically signifi-
cant association between elevated cortisol levels and the develop-
ment of ICSCR, whereas no significant differences in testosterone 
levels were noted and levels remained within the normal range 
in both groups. A case-control study (118) of chronic ICSCR 
reported that cortisol and testosterone levels were similar in both 
groups. Though there appears to be a correlation between hor-
mones and ICSCR, conflicting evidence leaves many questions 
about the etiopathogenesis and treatment of CSCR open.
Macular Hole
Evidence of Estrogen Protection in the Macular Hole
Macular hole is a major cause of diminished vision, especially in 
advanced age. Although in some cases the cause can be identi-
fied, e.g., contusive trauma (119), cystoid macular edema (120), 
or diabetes (121), it is idiopathic in the majority and thought 
to be due to circumferential vitreoretinal contraction (122). 
Macular hole affects women far more often than men (123). As 
in other eye diseases, it is thought that estrogens have a beneficial 
effect on macular health and protect against the development 
of macular hole. For example, estrogens stimulate the synthesis 
of collagen and hyaluronic acid in the skin, suggesting that a 
similar process might also occur in the eye. With the sudden 
drop in estrogen production after menopause, this protection 
is lost, posing the retina to a higher risk than that for men, in 
whom estrogen levels are generally low throughout life and do 
not change abruptly. In addition to menopause, early hyster-
ectomy or HRT may influence estrogen activity in relation to 
the development of macular holes (124, 125). Current evidence 
indicates strong correlations between macular hole and female 
sex and postmenopausal age (126), as demonstrated by various 
studies. A population-based study showed a female-to-male 
ratio of 3.3:1 for full-thickness macular hole (127). In their 
case-control study, Evans et al. (128) found that 67% of persons 
with macular hole were women and that 74% of the women were 
aged 65 years or older. The study analyzed various risk factors, 
including ethnic origin, systemic comorbidities, current use and 
history of medications, alcohol intake, smoking, body weight 
and height, menstrual and obstetric history, age at menopause 
and severity of associated symptoms, and exposure to HRT. The 
study findings indicated few systemic factors associated with 
idiopathic full-thickness macular hole (IFTMH), and though 
sex-correlated, no association was found between the principal 
indicators of exposure to estrogens and the incidence of macular 
hole. Nonetheless, a role for estrogens was suggested by the fact 
that women with macular hole generally experienced a more 
difficult menopause and more bothersome climacteric symp-
toms such as hot flashes than healthy women. The results also 
suggested that the development of IFTMH may be more due to 
the sudden change in hormone levels that chronic exposure, as 
demonstrated by the higher risk is associated with menopause, 
hysterectomy, and oophorectomy.
Correlations have been found between tamoxifen and 
macular hole and its precursor lesions (129). Tamoxifen is an 
anti-estrogenic nonsteroid drug used in adjuvant therapy for 
breast cancer (130). In this case report, all three women were 
receiving tamoxifen therapy and presented with cystic changes 
of the foveal region and defects of the external retina suggestive 
of initial macular hole.
A Study Shows That Estrogen Could Have a Negative 
Effect on Macular Hole
Another study investigated whether there were differences 
between the estrogen levels in the vitreous of subjects with 
macular hole and in those with other retinal disorders, who 
served as controls (131). The estrogen concentration was signifi-
cantly higher in those with macular hole (p < 0.05), implicating 
it in the pathogenesis of the disorder. Since estrogens activate 
collagenase, this could be correlated with the development of 
vitreous collagen disorders; however, owing to the small study 
sample (10 cases and 9 controls), no definitive conclusions could 
be drawn.
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Retinitis Pigmentosa
Evidence of the Benefical Effect of Progestinic 
Therapy in Retinitis Pigmentosa
Retinitis pigmentosa refers to a group of inherited retinal degen-
erative disorders in which genetic mutations lead to the death of 
retinal photoreceptors (132). Although the mutations in several 
genes implicated in the development of the diseases are known, the 
mechanism by which they cause cell death is not fully understood 
and no effective treatment is currently available (133). Recent 
studies using mouse models have suggested Norgestrel, a synthetic 
analog of progesterone, as a potential agent (134). Norgestrel’s pro-
tective action has been demonstrated on retinal explants in vitro 
and in two different in vivo models of retinal degeneration: the 
one involving mice exposed to photostress-induced damage and 
the other involving mice with genetic mutations characteristic of 
retinitis pigmentosa. Both models showed a reduction in cell loss, 
with improvement in cell survival of about 70% (calculated on the 
basis of photoreceptor number, structural integrity, and function), 
indicating that apoptosis was interrupted or slowed. Although the 
mechanism of action is not yet fully understood, it is thought that 
norgestrel activates a survival pathway probably based on the 
increased expression of fibroblast growth factor 2 (FGF-2), a pow-
erful neurotrophic factor whose production is increased by retinal 
stress. Its action promotes cell survival and inhibits apoptosis by 
activating the intracellular cascades involving mitogen-activated 
protein kinase, PI3K, and protein kinase C (PKC). The involve-
ment of FGF-2 was demonstrated by measuring its changes in the 
control subjects who were administered only the vehicle and in the 
subjects receiving norgestrel therapy: the finding of higher FDG-2 
values after norgestrel administration confirmed the hypothesis. 
These findings were strengthened by the same research group in a 
subsequent study (135) in which they investigated the potential of 
norgestrel as therapy for retinal degeneration.
Other studies investigated the relationship between proges-
terone and progestrinics and retinitis pigmentosa (136) building 
on previous studies on progesterone in experimental models of 
acute brain damage in which the drug had shown a neuropro-
tective effect (137). The action of progesterone was analyzed to 
determine the number of surviving cells, as measured by elec-
troretinography, and the potential protective effect of the drug 
owing to its ability to limit damage by free radicals or to increase 
antioxidant defenses. The results showed a reduction in cell death 
and gliosis, with a statistically significant reduction in glutamate 
and a significant increase in reduced glutathione and oxidized 
glutathione. The study underlined the beneficial action of proges-
terone which exerts via multiple modes of action in protecting the 
retina during retinitis pigmentosa, suggesting its use or that of its 
analogs in the treatment of the disease.
Diabetic Retinopathy
The Uncertain Role of Sex Hormones in Diabetic 
Retinopathy
Poor glycemic control ultimately results in macrovascular and 
microvascular complications, affecting the kidney and the eye 
in persons with diabetes. Diabetic retinopathy is most common 
complication (138) and is present in 34.6% of diabetics (139). Two 
forms are distinguished: nonproliferative or early stage diabetic 
retinopathy, and proliferative or late stage retinopathy in which 
retinal neovascularization is evident, leading to increased risk of 
loss of vision due to retinal detachment, neovascular glaucoma, and 
vitreous hemorrhaging. Another common cause of loss of vision is 
macular edema, which may arise in any stage of retinopathy (140). 
Studies investigating the possible links between sex hormones and 
diabetic retinopathy have analyzed the incidence of the condition 
by sex and produced conflicting results (49). One possible explana-
tion for the discrepancies is the likely presence of confounding fac-
tors. Grisby et al. (141) compared the direct action of sex hormones 
on retinal cells and their action on vasculature, and found that 
various hormones are involved in the development and progres-
sion of retinopathy in diabetic patients. Androgens and androgen 
inhibitors appear to play both a causal and a protective role, since 
they increase blood pressure and the levels of adhesion molecules 
(ICAM and VCAM-1), with worsening of lipid levels. A low level 
is associated with the metabolic syndrome and may alter lipid, 
glycemic, and blood pressure values. Dehydroepiandrosterone has 
a proven protective effect against the damage of elevated glucose 
levels in pericytes (142). It is believed that the damage due to 
elevated glucose levels occurs mainly through oxidative mecha-
nisms. The toxicity of glucose and subsequent vascular damage 
manifest in four ways: activation of the PKC cascade; activation 
of aldoso-reductase; protein glycosylation; and activation of the 
hexosamine pathway. According to the so-called unifying therapy, 
the formation of free oxygen radicals underlies the mechanisms 
leading to glucose damage (143, 144).
As oxidative stress is implicated in the development and 
progression of diabetic retinopathy, studies have investigated the 
role of estrogens, which possess antioxidant properties. Estrogens 
stimulate the ERβ receptor and protect retinal cells against oxida-
tive stress through their ability to modulate the transcription of 
antioxidant genes and protect the mitochondria (145). Estrogens 
can exert a differential action depending on the stage of retinopa-
thy: during the initial stages, the proliferation of endothelial cells 
induced by estradiol has a beneficial effect and protects the retina 
by inducing repair processes, whereas during the proliferative 
stage, this same effect exacerbates the disease (146, 147). Selective 
estrogen receptor modulators (SERMs), including tamoxifen and 
raloxifen, act as antagonists or agonists of estrogen depending on 
the type of receptor to which they bind. In the retina, both drugs 
strongly antagonize estrogen-induced angiogenesis (147). From 
the multitude of data collected so far it is clear that the use of sex 
hormones or their antagonists in the treatment of retinopathy must 
be personalized based on sex, age, and stage of disease. Stimulation 
or hormonal modulation may provide a novel therapeutic option.
Other studies have investigated differences in electroretino-
graphic patterns in relation to neuroretinal function in men and 
women with type 2 diabetes, but not retinopathy to evaluate risk 
for neurodegenerative disease (148). The analysis showed that 
neuroretinal dysfunction leading to diabetic retinopathy was 
far more common among men than women, suggesting a sex-
related protective mechanism. This finding was corroborated in 
a minireview issued by the Berkeley School of Optometry (49) 
that noted a more frequent incidence of abnormal neuroretinal 
function in men with type 2 diabetes. It was also observed that 
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advanced proliferative retinopathy in type 1 diabetes more often 
affects men, that retinopathy is more likely present at diagnosis of 
diabetes in men, and that it is often more severe than in women.
HRT Does Not Influence Diabetic Retinopathy
A possible benefit of HRT for retinopathy in postmenopausal 
women has been studied (149); however, no connection between 
changes in retinopathy and the incidence of macular edema and 
exposure to exogenous estrogen could be established, indicating 
that, unlike its effects observed in other eye disorders, HRT has 
no effect on diabetic retinopathy.
Glaucoma
Benefical Effects of Estrogens in Glaucoma
Glaucoma, the second leading cause of blindness in the world 
(43), is a slow, progressive neurodegenerative disease character-
ized by gradual loss of RGC (150) and loss of vision (151). A 
recent review (152) examining possible correlations between 
glaucoma and estrogens reported that factors influencing the 
duration of estrogen exposure (e.g., age at menarche, use of oral 
contraceptives, bilateral ovariectomy, age at menopause) can raise 
the risk of POAG. A higher risk for POAG was associated with age 
at menarche over 13 years, as compared to age less than 12 years 
(153), and a 25% higher risk was noted in women who took oral 
contraceptives for more than 5 years (154). Bilateral ovariectomy 
before age 43 increased the risk of developing glaucoma (155), as 
did spontaneous menopause before age 45 years (156), whereas 
the risk was significantly lower in women over age 65 who entered 
menopause after age 54 years (154). Prolonged estrogen exposure 
reduced the risk of glaucoma or glaucoma-related conditions, as 
demonstrated by evidence that IOP is lower during pregnancy 
when estrogen levels are elevated, particularly during the third 
trimester (157, 158). Evidence for a protective effect of HRT 
against glaucoma is uneven (79, 159, 160).
Genetic factors may also play a role in increasing the risk for 
developing glaucoma. SNPs implicated in the estrogen metabolic 
pathway associated with women, but not men (161), and polymor-
phisms of the endothelial nitric oxide synthase gene encoding the 
enzyme regulated by estrogens are correlated with the develop-
ment of open-angle glaucoma (162). Estrogen exposure may alter 
the pathogenesis of glaucoma and exert a neuroprotective action. 
A future area of focus is the use of estrogens in glaucoma treatment 
or prevention. Numerous studies have reported an association 
between estrogens and glaucoma; for example, estrogen deficiency 
was associated with the acceleration of aging of the optic nerve 
(163). Estrogens have also been implicated in aqueous humor pro-
duction and drainage via receptors on the ciliary epithelium (10, 
159). Changes in estrogen levels appear to influence IOP, which is 
responsible for optic nerve trophism (164). Epidemiology, clini-
cal, and experimental evidence supports the hypothesis that early 
reduction of estrogen levels leads to premature aging of the optic 
nerve and increased susceptibility to glaucoma.
In their study on the role of estrogens in modulating the topog-
raphy of the optic nerve head, Akar et al. (165) reported that, as 
observed in diabetic women, hormonal fluctuations during the 
menstrual cycle affect the central area and the margin of the optic 
nerve head. Genetic analysis to determine whether there exist 
associations between certain SNPs of genes involved in estrogen 
metabolism and the development of POAG (161) showed that 
SNPs were correlated with global POAG and POAG with elevated, 
but not with low IOP and no correlation of any type was noted for 
the men. Among the women, however, the gene that encodes the 
catechol-O-methyltransferase enzyme was found to be associated 
with open-angle glaucoma. Summarizing, links between SNPs of 
the estrogen pathways and the development of glaucoma were 
noted for certain types of glaucoma and only in women.
FUTURe PROSPeCTS AND 
OPPORTUNiTieS
A Place for HRT?
In light of the amount of research conducted so far on sex hor-
mones and neuroretinal diseases, the question arises whether and 
how it can be applied to the identification and development of 
new drugs or to expanding indications for drugs already on the 
market. An emblematic case is that of HRT for the treatment of 
climacteric symptoms.
Despite the wealth of data, the question remains open. A study 
evaluated the efficacy of HRT with phytoestrogens on eye function, 
as measured with short-wavelength automated perimetry in post-
menopausal women (166). Phytoestrogens are nonsteroids of plant 
origin with estrogen-like action in modulating vision sensitivity. 
Consistent with the theory of timing, which states that the benefits 
of HRT diminish the later the therapy is initiated, a loss of efficacy 
was noted in relation to the time between initiation of phytoestro-
gen therapy and onset of menopausal symptoms, with no benefit 
gained if the therapy was started in women over 60 years of age. No 
conclusions could be drawn from this study and no recommenda-
tions for the use of HRT for eye diseases could be made.
implications for Future Study Design
The present review of the literature found evidence for a sex-
related difference in the prevalence of certain eye diseases. A 
plausible explanation for the difference is the differential effect of 
sex hormones on the development and course of disease, which 
may be as meaningful as it is complex, though the underlying 
mechanisms are not yet fully understood.
The link between sex hormones and retinopathies opens 
new therapeutic horizons. To obtain a better understanding of 
the interactions between sex hormones and eye diseases, studies 
should be designed to determine the presence of an association 
between sex, hormones, and disease, and if such an association 
exists, the potential therapeutic correlates. To reach these objec-
tives, key areas of focus are: epidemiological studies on the 
distribution of eye disease in a population, while taking sex 
and hormonal status into account; experimental studies on the 
changes in the incidence and/or course of disease in relation to 
hormone administration or deprivation; and preclinical animal 
studies comparing differences between the sexes.
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